insights_auto
Why is ROIV down 2.76%?
Dive Deeperchevron_right
ROIV:NASDAQ
Roivant Sciences Ltd
$35.89
arrow_downward
-2.76%(-1.02) 1D
$35.89
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$36.95
High
$37.29
Low
$35.81
Mkt. cap
25.92B
Avg. vol.
6.47M
Volume
5.70M
52-wk high
$42.50
52-wk low
$19.30
EPS
-$0.39
Beta
1.10
Shares outstanding
722.32M
No. of employees
721
Open
$36.95
High
$37.29
Low
$35.81
Mkt. cap
25.92B
Avg. vol.
6.47M
Volume
5.70M
52-wk high
$42.50
52-wk low
$19.30
EPS
-$0.39
Beta
1.10
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Foreign Policy Journal
·
35 minutes ago
RTX Corporation's (NYSE: RTX) $271 Billion Backlog Fuels Analyst Optimism Despite Engine Concerns
Dealroom
·
39 minutes ago
Agility Robotics clears SPAC vote, expects $465M and Nasdaq debut November 5
investingLive
·
8 minutes ago
JPMorgan’s four midterm scenarios: S&P 500 seen moving between -0.25% and +1.25%
Bloomberg.com
·
4 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd
Analyst ratings
Based on 12 analysts giving stock ratings to ROIV in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ROIV in the last 3 months.
Highest
Current $35.89
$62.00 (+72.75%)
Average
$49.00 (+36.53%)
Lowest
$40.00 (+11.45%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst Leerink Partners | Buy | Maintained | $54.00 | +50.5% | 11/02/2026 |
Samantha Semenkow Citi | Buy | Maintained | $56.00 | +56% | 10/29/2026 |
Chi Meng Fong Bank of America Securities | Hold | Maintained | $41.00 | +14.2% | 10/21/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $62.00 | +72.8% | 10/21/2026 |
Douglas Tsao H.C. Wainwright | Buy | Maintained | $47.00 | +31% | 10/21/2026 |
Andy Chen Wolfe Research | Hold | Downgraded | - | - | 10/12/2026 |
Eve Burstein Bernstein | Buy | Maintained | $41.00 | +14.2% | 09/25/2026 |
Brian Cheng J.P. Morgan | Buy | Reiterated | - | - | 09/17/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Initiated | $51.00 | +42.1% | 09/17/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $46.00 | +28.2% | 09/08/2026 |
Dennis Ding Jefferies | Buy | Maintained | $52.00 | +44.9% | 09/08/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $40.00 | +11.5% | 08/28/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $42.00 | +17% | 08/18/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $40.00 | +11.5% | 04/16/2026 |
Corinne Johnson Goldman Sachs | Buy | Maintained | $41.00 | +14.2% | 04/15/2026 |
William Pickering Bernstein | Buy | Initiated | $35.00 | -2.5% | 03/20/2026 |
Next call in 6 days
Mon, Nov 9, 8:00 AM
Fiscal period
Q2 2027
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.45
Revenue / Est. (USD)
- / 4.11M
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.57M | 2.00M | 2.52M | 1.44M |
Cost of goods sold | 164.18M | 166.08M | 199.26M | 202.30M |
Cost of revenue | 164.18M | 166.08M | 199.26M | 202.30M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 129.52M | 175.05M | 155.97M | 165.53M |
Operating expense | 129.52M | 175.05M | 155.97M | 165.53M |
Total operating expenses | 293.70M | 341.13M | 355.23M | 367.83M |
Operating income | -292.13M | -339.14M | -352.71M | -366.38M |
Other non operating income | -26.65M | -16.07M | 7.47M | -2.93M |
EBT including unusual items | -159.04M | -290.37M | 454.10M | -294.56M |
EBT excluding unusual items | -273.44M | -311.94M | -298.96M | -331.59M |
Income tax expense | 7.00M | 23.33M | 98.35M | -3.96M |
Effective tax rate | -4.40% | -8.04% | 21.66% | 1.34% |
Other operating expenses | - | - | - | - |
Net income | -113.52M | -265.89M | 302.99M | -189.84M |
Net profit margin | -7,225.91% | -13,301.20% | 12,023.57% | -13,164.84% |
Earnings per share | -0.28 | -0.24 | -0.32 | -0.34 |
Interest and investment income | 45.34M | 43.27M | 41.18M | 36.92M |
Interest expense | - | - | - | - |
Net interest expenses | 45.34M | 43.27M | 41.18M | 36.92M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -291.21M | -338.44M | -352.07M | -365.78M |
Gain or loss from assets sale | - | - | -11.03M | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events